Table 2. Biological Pathways That Are Upregulated in PLX/AZD-Resistant Monolayers or Spheroids. Qiagen Ingenuity Pathway Analysis Was Used to Define the Biological Signaling Pathways with an Upregulated Activity in PLX/AZD-Resistant Monolayer (A) or Spheroid (B) Cell Cultures; where Significance Thresholds of Benjamini–Hochberg Corrected p < 0.05 and z-Scores Greater than 1.5 Were Used.
| A) Monolayers | ||
|---|---|---|
| Pathway | P-value | z-score |
| leukocyte extravasation signaling | 0.030 | 2.65 |
| TGF-β signaling | 0.038 | 2.24 |
| Rac signaling | 0.010 | 1.89 |
| B cell receptor signaling | 0.047 | 1.89 |
| PI3K/AKT signaling | 0.002 | 1.67 |
| glioma invasiveness signaling | 0.010 | 1.63 |
| B) Spheroids | ||
|---|---|---|
| Pathway | P-value | z-score |
| oxidative phosphorylation | <0.001 | 6 |
| TCA cycle II | <0.001 | 3.74 |
| fatty acid β-oxidation I | <0.001 | 3.32 |
| valine degradation I | <0.001 | 3 |
| isoleucine degradation I | 0.001 | 2.45 |
| glutathione redox reactions I | 0.005 | 2.45 |
| glioma signaling | 0.007 | 2.33 |
| NRF2-mediated oxidative stress response | 0.002 | 2.31 |
| leucine degradation I | 0.001 | 2.24 |
| ketolysis | 0.001 | 2.24 |
| ketogenesis | 0.001 | 2.24 |
| glutaryl-CoA degradation | 0.003 | 2.24 |
| AMPK signaling | 0.011 | 1.81 |
| stearate biosynthesis I | 0.002 | 1.67 |
| paxillin signaling | 0.003 | 1.51 |